The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) (SIRIUS-SLE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05624749
Recruitment Status : Recruiting
First Posted : November 22, 2022
Last Update Posted : May 20, 2024
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 26, 2027
Estimated Study Completion Date : January 23, 2029